April 16 (Reuters) - Apellis Pharmaceuticals Inc:
* APELLIS PHARMACEUTICALS PROVIDES UPDATE ON PHASE 1B OPEN LABEL STUDY OF APL-2 IN PNH PATIENTS NOT PREVIOUSLY TREATED WITH ECULIZUMAB
* APELLIS PHARMACEUTICALS INC - TO DATE, APL-2 HAS GENERALLY BEEN WELL-TOLERATED IN PATIENTS
* APELLIS PHARMACEUTICALS INC - EXPECTS TO REPORTING FURTHER UPDATES TO ONGOING PADDOCK TRIAL IN JUNE
* APELLIS - IN H2 2018, PLANS TO INITIATE A PHASE 3 TRIAL IN 70 PATIENTS WITH PNH VERSUS TREATMENT WITH APL-2 MONOTHERAPY TO TREATMENT WITH ECULIZUMAB Source text for Eikon: Further company coverage: